A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria

Key Points

Key points are not available for this paper at this time.

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disease, is associated with high maternal and fetal mortality rates. Only 1 medication approved for PNH, the complement component 5 inhibitor eculizumab, has published evidence of use during pregnancy.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Du et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6c1b7b6db643587640569 https://doi.org/https://doi.org/10.1016/j.rpth.2024.102435

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Paroxysmal Nocturnal Hemoglobinuria and the Risk of Venous Thrombosis: Review and Recommendations for Management of the Pregnant and Nonpregnant Patient2000 · 132 citations
2Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 · 379 citations
3Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study2022 · 5 citations
4Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience2011 · 54 citations
5Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria2015 · 275 citations

Bookmark

View Full Paper